GB2253348A — Sustained release compositions
Assigned to Reckitt Benckiser Healthcare UK Ltd · Expires 1992-09-09 · 34y expired
What this patent protects
The compositions comprise cores including a pharmacologically active ingredient and having a diameter not greater than 5 mm, the cores being coated with a mixture comprising a) as a film forming agent at least one poly (ethyl acrylate, methyl methacrylate, trimethylammonioethyl m…
USPTO Abstract
The compositions comprise cores including a pharmacologically active ingredient and having a diameter not greater than 5 mm, the cores being coated with a mixture comprising a) as a film forming agent at least one poly (ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) and b) at least one anionic surfactant wherein the ratio of a) to b) is from 100:1 to 10:1 by weight. The surfactant may be an alkylaryl sulphonate, sodium lauryl sulphate, a sulphosuccinate, a sulphosuccinamate, a sarcosinate or a taurate and the active ingredient may be (inter alia) idazoxan mebeverine, paracetamol, aspirin or betahistine. The film forming agent may be Eudragit RS or Eudragit RL (Trade Marks).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.